Page 266 - Young, black and stigmatised: how haematologists harm patients with sickle cell disease

Dr Stephen Hibbs and Dr Sonia Wolf

References

  1. Strouse J, Lobner K, Lanzkron S, Haywood C. NIH and National Foundation Expenditures For Sickle Cell Disease and Cystic Fibrosis Are Associated With Pubmed Publications and FDA Approvals. Blood. 2013;122:1739 
  2. AlJuburi G, Laverty A, Green S, Phekoo K, Bell D, Majeed A. Socio-economic deprivation and risk of emergency readmission and inpatient mortality in people with sickle cell disease in England: Observational study. Journal of Public Health 2013;35(4):510–517.
  3. Shapiro BS, Benjamin LJ, Payne R, Heidrich G. Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manag.1997;14(3):168–74
  4. Elander J, Lusher J, Bevan D, Telfer P, Burton B. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. J Pain Symptom Manag.